WO2000004868A3 - Libraries of polyhydroxamates and their analogs - Google Patents

Libraries of polyhydroxamates and their analogs Download PDF

Info

Publication number
WO2000004868A3
WO2000004868A3 PCT/US1999/016848 US9916848W WO0004868A3 WO 2000004868 A3 WO2000004868 A3 WO 2000004868A3 US 9916848 W US9916848 W US 9916848W WO 0004868 A3 WO0004868 A3 WO 0004868A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyhydroxamate
matrix
analog
polyhydroxamates
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/016848
Other languages
French (fr)
Other versions
WO2000004868A2 (en
Inventor
Garland R Marshall
Leonard O Rosik
Otto F Schall
Urszula J Slomczynska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
METAPHORE Inc
Original Assignee
METAPHORE Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by METAPHORE Inc filed Critical METAPHORE Inc
Priority to CA002337756A priority Critical patent/CA2337756A1/en
Priority to EP99937465A priority patent/EP1098659A4/en
Priority to JP2000560861A priority patent/JP2002521319A/en
Priority to AU52295/99A priority patent/AU5229599A/en
Publication of WO2000004868A2 publication Critical patent/WO2000004868A2/en
Publication of WO2000004868A3 publication Critical patent/WO2000004868A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method of synthesizing desired polyhydroxamates and polyhydroxamate analogs is provided. The method comprises linking a first component of the desired polyhydroxamate or polyhydroxamate analog to a support matrix under conditions effective to form a first matrix-bound intermediate of said desired polyhydroxamate or analog, extending said first matrix-bound intermediate using reagents and reaction conditions effective to form one or more additional matrix-bound intermediates of said desired polyhydroxamate or analog, thereby forming a matrix-bound precursor of the desired polyhydroxamate or polyhydroxamate analog. Protective groups used during synthesis of the precursor are removed and the matrix-bound precursor is cleared from the support matrix, thereby synthesizing the desired polyhydroxamate or polyhydroxamate analog. Methods of making, screening and selecting libraries of candidate polyhydroxamates, the libraries and polyhydroxamates, polyhydroxamate analogs, their intermediates, and methods for using such compounds and their compositions are also disclosed.
PCT/US1999/016848 1998-07-23 1999-07-23 Libraries of polyhydroxamates and their analogs Ceased WO2000004868A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002337756A CA2337756A1 (en) 1998-07-23 1999-07-23 Libraries of polyhydroxamates and their analogs
EP99937465A EP1098659A4 (en) 1998-07-23 1999-07-23 Libraries of polyhydroxamates and their analogs
JP2000560861A JP2002521319A (en) 1998-07-23 1999-07-23 Library of polyhydroxamates and their analogs
AU52295/99A AU5229599A (en) 1998-07-23 1999-07-23 Libraries of polyhydroxamates and their analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9388398P 1998-07-23 1998-07-23
US60/093,883 1998-07-23

Publications (2)

Publication Number Publication Date
WO2000004868A2 WO2000004868A2 (en) 2000-02-03
WO2000004868A3 true WO2000004868A3 (en) 2000-05-04

Family

ID=22241527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016848 Ceased WO2000004868A2 (en) 1998-07-23 1999-07-23 Libraries of polyhydroxamates and their analogs

Country Status (5)

Country Link
EP (1) EP1098659A4 (en)
JP (1) JP2002521319A (en)
AU (1) AU5229599A (en)
CA (1) CA2337756A1 (en)
WO (1) WO2000004868A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916799B2 (en) 1997-11-03 2005-07-12 Duke University Substituted porphyrins
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312103T1 (en) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center SUBSTITUTED PORPHYRINS AND THEIR THERAPEUTIC USES
EP1330654B1 (en) * 2000-10-23 2006-03-08 Genetics Institute, LLC Acid-labile isotope-coded extractant (alice) in mass spectometric analysis
EP1439842A4 (en) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center OXIDIZING SENSORS FOR THE TREATMENT OF DIABETES OR FOR USE IN TRANSPLANTATION OR INDUCING IMMUNE TOLERANCE
US20040236519A1 (en) * 2001-06-08 2004-11-25 Marshall Garland R. Libraries of confomationally constrained peptides, chiral azacrowns, and peptidomimetics and methods of making the same
DK2300003T3 (en) 2008-05-23 2014-05-26 Nat Jewish Health Compounds for use in treating damage associated with exposure to an alkylating species
US9334716B2 (en) 2012-04-12 2016-05-10 Halliburton Energy Services, Inc. Treatment fluids comprising a hydroxypyridinecarboxylic acid and methods for use thereof
US11033642B2 (en) * 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
SG11202010016QA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
CN110270133A (en) * 2019-07-30 2019-09-24 深圳市百迈生命科学有限公司 A kind of integral post plate preparation method and application based on PE sieve plate conjugation chemistry group

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987253A (en) * 1988-09-19 1991-01-22 University Of Florida Method for the synthesis of desferrioxamine B and analogs thereof
WO1996026223A1 (en) * 1995-02-24 1996-08-29 British Biotech Pharmaceuticals Limited Synthesis of hydroxamic acid derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322961A (en) * 1992-12-09 1994-06-21 University Of Florida Analogs of desferrioxamine B and method for synthesis thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987253A (en) * 1988-09-19 1991-01-22 University Of Florida Method for the synthesis of desferrioxamine B and analogs thereof
WO1996026223A1 (en) * 1995-02-24 1996-08-29 British Biotech Pharmaceuticals Limited Synthesis of hydroxamic acid derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERGERON ET AL.: "Structural Alterations in Desferrioxamine Compatible with Iron Clearance in Animals", J. MED. CHEM.,, vol. 35, no. 25, 1992, pages 4739 - 4744, XP002925124 *
BERGERON ET AL.: "Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators", J. MED. CHEM.,, vol. 34, no. 11, 1991, pages 3182 - 3187, XP002925122 *
DIONIS ET AL.: "Synthesis and Analytical Characterization of a Major Desferrioxamine B Metabolite", J. ORG. CHEM.,, vol. 54, no. 23, 1989, pages 5623 - 5627, XP002925123 *
FURKA ET AL.: "General Method for Rapid Synthesis of Multicomponent Mixtures", INT. J. PEPTIDE PROTEIN RES.,, vol. 37, 1991, pages 487 - 493, XP002925121 *
GOLEBIOASKI ET AL.: "Solid Supported Synthesis of Hydroxamic Acids", TET. LETT.,, vol. 39, no. 21, 21 May 1998 (1998-05-21), pages 3397 - 3400, XP002925120 *
GORDON ET AL.: "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies and Future Directions", J. MED. CHEM.,, vol. 37, no. 10, 13 May 1994 (1994-05-13), pages 1385 - 1401, XP002925118 *
NGU ET AL.: "A New and Efficient Solid Phase Synthesis of Hydroxamic Acids", J. ORG. CHEM.,, vol. 62, no. 21, 17 October 1997 (1997-10-17), pages 7088 - 7089, XP002925119 *
See also references of EP1098659A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US6916799B2 (en) 1997-11-03 2005-07-12 Duke University Substituted porphyrins
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins

Also Published As

Publication number Publication date
CA2337756A1 (en) 2000-02-03
EP1098659A4 (en) 2004-11-24
EP1098659A2 (en) 2001-05-16
AU5229599A (en) 2000-02-14
JP2002521319A (en) 2002-07-16
WO2000004868A2 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
Okada et al. Efficient general method for sulfamoylation of a hydroxyl group
DE60020340D1 (en) SYNTHESIS PROCEDURES FOR THE ECONOMIC STRUCTURE OF LONG DNA SEQUENCES AND COMPOSITIONS THEREFOR
EP1020534A4 (en) Process for synthesizing nucleic acid
EP1386922A3 (en) Synthesis of epothilones, intermediates thereof, analogues and uses thereof
CA2187969A1 (en) A template for solution phase synthesis of combinatorial libraries
CA2016841A1 (en) A method for producing polymers having a preselected activity
ZA994059B (en) Process for the preparation of hydrocarbon from synthesis gas.
EP1956014A3 (en) Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
CA2266081A1 (en) Process for producing ecteinascidin compounds
AU2810097A (en) Process for removal of hydrogen cyanide from synthesis gas
CA2484526A1 (en) Synthesis of locked nucleic acid derivatives
CA2301639A1 (en) 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same
ES2157466T3 (en) PROCEDURE FOR PREPARATION OF COMPOUNDS WITH BETA-HIDROXI-DELTA-LACTONA GROUP ANALOGS OF THE (+) COMPACTINE AND THE (+) MEVINOLINA.
ZA972890B (en) Production of synthesis gas from hydrocarbonaceous feedstock.
Xu et al. A new approach to 1-deoxy-azasugars: Asymmetric synthesis of deoxymannojirimycin
ATE457972T1 (en) METHOD FOR PRODUCING 7-AMINO-SYN-3,5-DIHYDROXYHEPTANIC ACID DERIVATIVES AND INTERMEDIATE COMPOUNDS OF THIS METHOD AND THEIR PRODUCTION
CA2276213A1 (en) Method of synthesizing phosphorothioate oligonucleotides
WO1997008190A3 (en) Compounds
WO2001094317A3 (en) Method for synthesis of substituted azole libraries
HU9700667D0 (en) Process for producing intermediates for the synthesis of iodinated kontrast materials
CA2269589A1 (en) A solid-phase technology for the preparation of amides
WO1999064379A3 (en) Biomimetic combinatorial synthesis
Ishibashi et al. Syntheses of (±)-Haedoxan A, D, E and their stereoisomers
McComsey et al. Improved synthesis of pseudo-. beta.-D-fructopyranose, a carbocyclic monosaccharide from (-)-quinic acid
EP1199308A3 (en) Process for the preparation of imidazodiazepine intermediates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 508768

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 52295/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2337756

Country of ref document: CA

Ref country code: CA

Ref document number: 2337756

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 560861

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999937465

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999937465

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999937465

Country of ref document: EP